SEC Allows Serum Institute To Conduct Novavax’s Bridging Trials In India
New Delhi: Serum Institute of India (SII) got the approval to conduct Phase 2 and 3 clinical trials for Novavax’s COVID-19 vaccine candidate in the country. The green signal came from Subject Expert Committee (SEC) of India’s central drug…